The collection of NFATc1-dependent transcripts in the osteoclast includes numerous genes non-essential to physiologic bone resorption

Bone

Volumn 51, Issue 5, 2012, Pages 902-912

  Charles, Julia F ^a   Coury, Fabienne ^b,c,f   Sulyanto, Rosalyn ^b,g   Sitara, Despina ^b,h   Wu, Jing ^b,i   Brady, Nicholas ^b,j   Tsang, Kelly ^b   Sigrist, Kirsten ^b,k   Tollefsen, Douglas M ^d   He, Li ^d   Storm, Daniel ^e   Aliprantis, Antonios O ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITÉ DE LYON   (France)

^g OCC Dentistry   (United States)

^h NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

ⁱ Novartis Institutes for Biomedical Research   (China)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^k BROWN UNIVERSITY   (United States)

more..

Author keywords

Bone resorption; Gene array; NFATc1; NHEDC2; Osteoclast

Indexed keywords

MESSENGER RNA; NUCLEAR FACTOR OF ACTIVATED T CELL C1; OSTEOCLAST DIFFERENTIATION FACTOR; REGULATOR PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADCY3 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC IDENTIFICATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NHEDC2 GENE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PHENOTYPIC VARIATION; PHYSIOLOGICAL PROCESS; RAB38 GENE; REGULATOR GENE; RHOC GENE; SERPIND1 GENE; SIGNAL TRANSDUCTION; WILD TYPE;

ADENYLATE CYCLASE; ANIMALS; BLOTTING, WESTERN; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; MICE; NFATC TRANSCRIPTION FACTORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOCLASTS; RAB GTP-BINDING PROTEINS; RANK LIGAND; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SODIUM-HYDROGEN ANTIPORTER;

EID: 84867070689     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.08.113     Document Type: Article

References (49)

1. Sims N.A., Gooi J.H. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008, 19:444-451.
2. Miller P.D. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009, 7:18-22.
3. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
4. Rizzoli R., Reginster J.Y., Boonen S., Breart G., Diez-Perez A., Felsenberg D., et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011, 89:91-104.
5. Woo S.B., Hellstein J.W., Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
6. Sellmeyer D.E. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010, 304:1480-1484.
7. Jonsson B., Strom O., Eisman J.A., Papaioannou A., Siris E.S., Tosteson A., et al. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011, 22:967-982.
8. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009, 5:667-676.
9. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q., et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 2011, 17:1231-1234.
10. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation. Nat Med 2011, 17:1235-1241.
11. Jones D., Glimcher L.H., Aliprantis A.O. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest 2011, 121:2534-2542.
12. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
13. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007, 1116:227-237.
14. Aliprantis A.O., Ueki Y., Sulyanto R., Park A., Sigrist K.S., Sharma S.M., et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 2008, 118:3775-3789.
15. Winslow M.M., Pan M., Starbuck M., Gallo E.M., Deng L., Karsenty G., et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell 2006, 10:771-782.
16. Asagiri M., Sato K., Usami T., Ochi S., Nishina H., Yoshida H., et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005, 202:1261-1269.
17. Aliprantis A.O., Stolina M., Kostenuik P.J., Poliachik S.L., Warner S.E., Bain S.D., et al. Transient muscle paralysis degrades bone via rapid osteoclastogenesis. FASEB J 2012, 26:1110-1118.
18. Sitara D., Aliprantis A.O. Transcriptional regulation of bone and joint remodeling by NFAT. Immunol Rev 2010, 233:286-300.
19. - anion exchanger SLC4A2 is required for proper osteoclast differentiation and function. Proc Natl Acad Sci U S A 2008, 105:16934-16939.
20. Meyers S.N., McDaneld T.G., Swist S.L., Marron B.M., Steffen D.J., O'Toole D., et al. A deletion mutation in bovine SLC4A2 is associated with osteopetrosis in Red Angus cattle. BMC Genomics 2010, 11:337.
21. Kuhn R., Schwenk F., Aguet M., Rajewsky K. Inducible gene targeting in mice. Science 1995, 269:1427-1429.
22. He L., Vicente C.P., Westrick R.J., Eitzman D.T., Tollefsen D.M. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002, 109:213-219.
23. Wong S.T., Trinh K., Hacker B., Chan G.C., Lowe G., Gaggar A., et al. Disruption of the type III adenylyl cyclase gene leads to peripheral and behavioral anosmia in transgenic mice. Neuron 2000, 27:487-497.
24. Hakem A., Sanchez-Sweatman O., You-Ten A., Duncan G., Wakeham A., Khokha R., et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005, 19:1974-1979.
25. Loftus S.K., Larson D.M., Baxter L.L., Antonellis A., Chen Y., Wu X., et al. Mutation of melanosome protein RAB38 in chocolate mice. Proc Natl Acad Sci U S A 2002, 99:4471-4476.
26. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. [Article3].
27. Benjamini Y., Hochberg Y. Controlling the false discover rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol 1995, 57(1):289-300.
28. Ware C.B., Horowitz M.C., Renshaw B.R., Hunt J.S., Liggitt D., Koblar S.A., et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 1995, 121:1283-1299.
29. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
30. Hofstetter W., Siegrist M., Simonin A., Bonny O., Fuster D.G. Sodium/hydrogen exchanger NHA2 in osteoclasts: subcellular localization and role in vitro and in vivo. Bone 2010, 47:331-340.
31. + exchanger domain containing 2 and its role in osteoclast fusion. Proteomics 2008, 8:2625-2639.
32. Tollefsen D.M. Heparin cofactor II modulates the response to vascular injury. Arterioscler Thromb Vasc Biol 2007, 27:454-460.
33. Church F.C., Noyes C.M., Griffith M.J. Inhibition of chymotrypsin by heparin cofactor II. Proc Natl Acad Sci U S A 1985, 82:6431-6434.
34. Pratt C.W., Tobin R.B., Church F.C. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G. J Biol Chem 1990, 265:6092-6097.
35. Yoon S.H., Ryu J., Lee Y., Lee Z.H., Kim H.H. Adenylate cyclase and calmodulin-dependent kinase have opposite effects on osteoclastogenesis by regulating the PKA-NFATc1 pathway. J Bone Miner Res 2011, 26:1217-1229.
36. Raisz L.G., Vanderhoek J.Y., Simmons H.A., Kream B.E., Nicolaou K.C. Prostaglandin synthesis by fetal rat bone in vitro: evidence for a role of prostacyclin. Prostaglandins 1979, 17:905-914.
37. Takami M., Cho E.S., Lee S.Y., Kamijo R., Yim M. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 2005, 579:832-838.
38. Sheridan C.M., Heist E.K., Beals C.R., Crabtree G.R., Gardner P. Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J Biol Chem 2002, 277:48664-48676.
39. Wang Z., Li V., Chan G.C., Phan T., Nudelman A.S., Xia Z., et al. Adult type 3 adenylyl cyclase-deficient mice are obese. PLoS One 2009, 4:e6979.
40. Itzstein C., Coxon F.P., Rogers M.J. The regulation of osteoclast function and bone resorption by small GTPases. Small Gtpases 2011, 2:117-130.
41. Croke M., Ross F.P., Korhonen M., Williams D.A., Zou W., Teitelbaum S.L. Rac deletion in osteoclasts causes severe osteopetrosis. J Cell Sci 2011, 124:3811-3821.
42. Ito Y., Teitelbaum S.L., Zou W., Zheng Y., Johnson J.F., Chappel J., et al. Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization. J Clin Invest 2010, 120:1981-1993.
43. Wang Y., Lebowitz D., Sun C., Thang H., Grynpas M.D., Glogauer M. Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis. J Bone Miner Res 2008, 23:260-270.
44. Zhang D., Udagawa N., Nakamura I., Murakami H., Saito S., Yamasaki K., et al. The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995, 108(Pt 6):2285-2292.
45. Zhao H., Laitala-Leinonen T., Parikka V., Vaananen H.K. Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol Chem 2001, 276:39295-39302.
46. Pavlos N.J., Xu J., Riedel D., Yeoh J.S., Teitelbaum S.L., Papadimitriou J.M., et al. Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol 2005, 25:5253-5269.
47. Seto S., Tsujimura K., Koide Y. Rab GTPases regulating phagosome maturation are differentially recruited to mycobacterial phagosomes. Traffic 2011, 12:407-420.
48. Osanai K., Higuchi J., Oikawa R., Kobayashi M., Tsuchihara K., Iguchi M., et al. Altered lung surfactant system in a Rab38-deficient rat model of Hermansky-Pudlak syndrome. Am J Physiol Lung Cell Mol Physiol 2010, 298:L243-L251.
49. Wheeler A.P., Ridley A.J. Why three Rho proteins? RhoA, RhoB, RhoC, and cell motility. Exp Cell Res 2004, 301:43-49.